{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:39:17Z","timestamp":1783694357213,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Science, Research and Arts of Baden W\u00fcrttemberg","award":["SI-BW 01222-91"],"award-info":[{"award-number":["SI-BW 01222-91"]}]},{"name":"Deutsche Forschungsgemeinschaft DFG (German Research Foundation)","award":["INST 2388\/33-1"],"award-info":[{"award-number":["INST 2388\/33-1"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.exer.2018.06.009","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T08:53:18Z","timestamp":1529052798000},"page":"166-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Influence of aflibercept on platelet activation profile"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-6873","authenticated-orcid":false,"given":"B.","family":"Sobolewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Golenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Poeschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Grimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gatsiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sopova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8066-5157","authenticated-orcid":false,"given":"K.","family":"Schenke-Layland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Stellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2018.06.009_bib1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jth.12905","article-title":"Human platelet IgG Fc receptor FccRIIA in immunity and thrombosis","volume":"13","author":"Arman","year":"2015","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.exer.2018.06.009_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema. A systemic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.exer.2018.06.009_bib3","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.06.009_bib4","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.exer.2018.06.009_bib5","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood-2008-02-142125","article-title":"Identification of Fc\u03b3RIIa as the ITAM-bearing receptor mediating \u03b1IIb\u03b23 outside-in integrin signaling in human platelets","volume":"112","author":"Boylan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exer.2018.06.009_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1538-7836.2007.02361.x","article-title":"Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin","volume":"5","author":"Chauhan","year":"2007","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.exer.2018.06.009_bib7","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-12-2911","article-title":"Aflibercept","volume":"19","author":"Ciombor","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.exer.2018.06.009_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11888-015-0292-3","article-title":"Update on anti-angiogenesis therapy in colorectal cancer","volume":"11","author":"Ciombor","year":"2015","journal-title":"Curr. Colorectal Canc. Rep."},{"key":"10.1016\/j.exer.2018.06.009_bib9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1517\/14712598.2012.707176","article-title":"Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration","volume":"12","author":"Costagliola","year":"2012","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.exer.2018.06.009_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.exer.2013.07.018","article-title":"VEGF but not PIGF disturbs the barrier of retinal endothelial cells","volume":"115","author":"Deissler","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.06.009_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.exer.2014.02.024","article-title":"Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells","volume":"122","author":"Deissler","year":"2014","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.06.009_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.exer.2016.11.007","article-title":"Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through endothelial cells","volume":"154","author":"Deissler","year":"2017","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.06.009_bib13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1160\/TH06-12-0725","article-title":"Hyperresponsiveness of platelets in ischemic stroke","volume":"97","author":"Fateh-Moghadam","year":"2007","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.exer.2018.06.009_bib14","article-title":"The influence of bevacizumab on platelet function","volume":"141","author":"Fehr","year":"2011","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.exer.2018.06.009_bib15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2018.06.009_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-2125.2012.04212.x","article-title":"Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review","volume":"74","author":"Hasan","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.exer.2018.06.009_bib17","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"VIEW 1 and VIEW 2 study groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.06.009_bib18","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular Toxicities of cancer therapies the old and the new \u2013 an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2018.06.009_bib19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncol."},{"key":"10.1016\/j.exer.2018.06.009_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrc2561","article-title":"Regulation of nitric oxide signaling by thrombospondin-1: implications for anti-angiogenic therapies","volume":"9","author":"Isenberg","year":"2009","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.exer.2018.06.009_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1160\/TH09-03-0192","article-title":"Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis","volume":"102","author":"Jennings","year":"2009","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.exer.2018.06.009_bib22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/bjophthalmol-2012-302308","article-title":"In vitro induction of protein complexes between bevacizumab, VEGF-A165 and heparin: explanation for deposits observed on endothelial veins in monkey eyes","volume":"97","author":"Julien","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.06.009_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.2008.17.7931","article-title":"Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials","volume":"27","author":"Kabbinavar","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.exer.2018.06.009_bib24","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/bjophthalmol-2014-305105","article-title":"Effect of aflibercept on primary RPE cells: toxicity, wound healing uptake and phagocytosis","volume":"98","author":"Klettner","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.06.009_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10456-016-9515-8","article-title":"Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes","volume":"19","author":"MacDonald","year":"2016","journal-title":"Angiogenesis"},{"key":"10.1016\/j.exer.2018.06.009_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/eye.2011.66","article-title":"Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab","volume":"25","author":"Meyer","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.exer.2018.06.009_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clcc.2013.04.006","article-title":"FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials","volume":"12","author":"Petrelli","year":"2013","journal-title":"Clin. Colorectal Canc."},{"key":"10.1016\/j.exer.2018.06.009_bib28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.exer.2018.06.009_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/bjophthalmol-2014-305149","article-title":"Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis","volume":"99","author":"Schmid","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.06.009_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.06.009_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use","volume":"7","author":"Semeraro","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.exer.2018.06.009_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000437057","article-title":"Different effects of ranibizumab and bevacizumab on platelet activation profile","volume":"234","author":"Sobolewska","year":"2015","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.exer.2018.06.009_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1538-7836.2009.03659.x","article-title":"Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication","volume":"8","author":"Stellos","year":"2010","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.exer.2018.06.009_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-0030-1251502","article-title":"Platelets in regeneration","volume":"36","author":"Stellos","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.exer.2018.06.009_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1538-7836.2011.04547.x","article-title":"Expression of platelet-bound stromal cell-derived factor-1 in patients with non-valvular atrial fibrillation and ischemic heart disease","volume":"10","author":"Stellos","year":"2012","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.exer.2018.06.009_bib36","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq702","article-title":"Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab","volume":"22","author":"Tebbutt","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.exer.2018.06.009_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaophthalmol.2018.0002","article-title":"Overview of systematic reviews and meta-analyses on systemic adverse events associated with intravitreal anti-vascular endothelial growth factor medication use","volume":"136","author":"Thulliez","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.exer.2018.06.009_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11936-018-0635-x","article-title":"Arterial thrombosis in patients with cancer","volume":"20","author":"Tuzovic","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.exer.2018.06.009_bib39","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.exer.2018.06.009_bib41","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1158\/1078-0432.CCR-07-0847","article-title":"Platelets take up the mono- clonal antibody bevacizumab","volume":"13","author":"Verheul","year":"2007","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.exer.2018.06.009_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10456-018-9598-5","article-title":"Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab","volume":"21","author":"Walvaren","year":"2018","journal-title":"Angiogenesis"},{"key":"10.1016\/j.exer.2018.06.009_bib43","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","article-title":"Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis \u2013 implications for cardiovascular safety","volume":"168","author":"Winnik","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.exer.2018.06.009_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2011.06.082","article-title":"Platelet expression of stromal-cell-derived factor-1 (SDF-1): an indicator for ACS?","volume":"164","author":"Wurster","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.exer.2018.06.009_bib45","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1073\/pnas.1109029108","article-title":"Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy","volume":"108","author":"Yao","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.exer.2018.06.009_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14740338.2016.1121232","article-title":"Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues","volume":"15","author":"Ziemssen","year":"2016","journal-title":"Expet Opin. Drug Saf."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483518300484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483518300484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T18:19:48Z","timestamp":1604427588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483518300484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":45,"alternative-id":["S0014483518300484"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2018.06.009","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of aflibercept on platelet activation profile","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2018.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}